Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

by | May 20, 2026 | Clinical Trials | 0 comments

​ Conditions: Hypertrophic Cardiomyopathy (HCM)

Interventions: Drug: Aficamten

Sponsors: Oregon Health and Science University; Saint Lukes Hospital Mid America Heart Institute; Cytokinetics

Recruiting Conditions: Hypertrophic Cardiomyopathy (HCM)
Interventions: Drug: Aficamten
Sponsors: Oregon Health and Science University; Saint Lukes Hospital Mid America Heart Institute; Cytokinetics
Recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *